Identification of diagnostic and prognostic host biomarkers of Zika virus infection by transcriptome profiling NIH R21AI129455 Dec 14, 2016 - Role: Principal Investigator Chiu has authored more than 50 peer-reviewed publications, holds over 15 patents and patent applications, and serves on the scientific advisory board for Therabio, Karius, and Rubicon Genomics.ĭiscovery and clinical validation of host biomarkers of disease severity and multi-system inflammatory syndrome in children (MIS-C) with Covid-19 NIH R61HD105618 Jan 1, 2021 - Role: Principal Investigator His work is supported by research grants from the NIH, Abbott Laboratories, Bay Area Lyme Disease Foundation, Global Lyme Alliance, USAID PREDICT program, UC Center for Accelerated Innovation, Sandler / Bowes Foundation, and California Initiative to Advance Precision Medicine.
#Charles payne illness software#
He heads a translational research laboratory engaged in clinical next-generation sequencing assay development for diagnosis of infectious diseases, pathogen discovery, bioinformatics software development, nanopore sequencing, and characterization of emerging infections (Lyme disease, enterovirus D68, and Zika virus).
Chiu obtained an MD and PhD in biophysics from UCLA and subsequently completed an internal medicine residency, infectious diseases fellowship, and postdoctoral research at UCSF. is a Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases at University of California, San Francisco, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory, He is a board-certified consulting infectious diseases physician at UCSF, and practices in both infectious diseases and clinical microbiology.
0 kommentar(er)
